Articles tagged "Immunosuppression"

2015 American Transplant Congress
A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA)
J. Trofe-Clark,^1,2 D. Brennan,³ P. West-Thielke,⁴ M. Milone,⁵ M. Lim,² R. Bloom.²
¹Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia; ²Renal Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia; ³Renal Division, Washington University, St. Louis; ⁴University of Illinois at Chicago, Chicago; ⁵Penn Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
The CYP3A5*1 genotype, highly prevalent in African Americans (AA), commonly necessitates higher tacrolimus (tac) dose requirements and may hinder efforts to obtain therapeutic drug levels.…
2015 American Transplant Congress
First Dose Tacrolimus Level Is Better Than CYP3A5 Genotyping in Prediction of Target Tacrolimus Dose
N. Townamchai,¹ W. Chancharoenthana,¹ S. Wattanatorn,¹ S. Vadcharavivad,² P. Chariyavilaskul,³ A. Leelahavanichkul,⁴ Y. Avihingsanon,¹ K. Praditpornsilpa.¹
¹Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; ²Department of Pharmacy Practice, Chulalongkorn University, Bangkok, Thailand; ³Pharmacokinetic Research Unit, Chulalongkorn University, Bangkok, Thailand; ⁴Department of Microbiology, Chulalongkorn University, Bangkok, Thailand.
Background: Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for…
2015 American Transplant Congress
Expanding the Living Donor Pool: Results of ABO Incompatible Living Related Kidney Transplantation
T. Vowinkel,¹ S. Reuter,² C. Anthoni,¹ N. Senninger,¹ B. Suwelack,² H. Wolters.¹
¹Department of General and Visceral Surgery, University Hospital Muenster, Muenster, Germany; ²Department of Medicine D, University Hospital Muenster, Muenster, Germany.
Background: Organ shortage has led to an increase in living related kidney transplantation. Here we report on our program of expanding the living donor pool…
2015 American Transplant Congress
Alloimmune Regulation and Long-Term Allograft Survival Induced by Short-Term Administration of Chinese Medicine Cornus Officinalis and Cuscuta Sinensis Lam
Z. Dai, Y. Zeng, X. Liu, Z. Chuan.
Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, China.
Achieving long-term allograft survival or tolerance without continuously global immunosuppression is a highly desirable goal. This study is to induce long-term allograft survival without long-term…
2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
G. Spagnoletti, M. Salerno, E. Favi, J. Pedroso, J. Romagnoli, F. Citterio.
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…
2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ I. Hauser,¹ P. Schenker,¹ D. Bäumer,² B. Nashan,¹ F. Thaiss.¹
¹Athena Study Group, Germany; ²Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…
2015 American Transplant Congress
Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study
A. Zuckermann,¹ M. Rinaldi,¹ N. Yonan,¹ S.-S. Wang,¹ G. Dong,² P. Lopez.²
¹For the A2309 Study Group, Vienna, Austria; ²Novartis, Basel, Switzerland.
Purpose: In the A2310 (NCT00300274) heart transplant (HTx) study with everolimus (EVR) vs mycophenolate mofetil (MMF), information on a broad spectrum of potential wound healing…
2015 American Transplant Congress
10 Year Experience Using a Steroid Free Three Drug Maintenance Immunosuppression Regimen for Pancreas Transplant Alone: Comparison of Induction With Rabbit Antithymocyte Globulin +/- Rituximab
J. Fridell,¹ R. Mangus,¹ J. Chen,² M. Mujtaba,³ T. Taber,³ M. Goble,¹ J. Powelson.¹
¹Surgery, Indiana University School of Medicine, Indianapolis, IN; ²Pharmacy, Indiana University School of Medicine, Indianapolis, IN; ³Medicine, Indiana University School of Medicine, Indianapolis, IN.
Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two drug maintenance strategy may be…
2015 American Transplant Congress
Effect of Everolimus on Left Ventricular Hypertrophy in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
M. van der Giet,¹ H. Holdaas,¹ J. de Fijter,¹ A. Speziale,² C. Escrig,² G. Junge,² Z. Wang,³ J. Cruzado.¹
¹For the ELEVATE Study, Berlin, Germany; ²Novartis, Basel, Switzerland; ³Novartis Corporation, East Hannover, NJ.
Background: Left ventricular hypertrophy (LVH) is common in kidney transplant recipients (KTxR) and has shown to be a risk factor for death and heart failure…
2015 American Transplant Congress
Plasmapheresis – A Previously Unrecognised Risk Factor for BK Viraemia
E. Olayos,¹ K. Barraclough,² R. Walker,³ R. Masterson,² H. Peter,² C. Solomon.⁴
¹St Vincents Hospital, Fitroy, Victoria, Australia; ²Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia; ³Nephrology, The Alfred Hospital, Prahran, Victoria, Australia; ⁴Nephrology, Western Hospital, Footscray, Victoria, Australia.
BK nephropathy is an important preventable cause of graft loss, with the only universally accepted risk factor being overall burden of immunosuppression. In the absence…